Advanced Oncotherapy uses proton beam therapy to target resistant cancers

  • Advanced Oncotherapy to raise GBP37.4mln as first proton beam therapy nears completion
  • Proton beam therapy will become as common as MRI scanning believes Advanced Oncotherapy’s chief executive
  • Advanced Oncotherapy builds commercial traction with Saba deal, says research house
  • Advanced Oncotherapy present research potentially offering ‘powerful weapon to resistant cancers’
cancer cell

Quick facts: Advanced Oncotherapy PLC


View company profile

Advanced Oncotherapy is a specialist developer and provider of a breakthrough proton therapy system, the LIGHT system, which is the result of 25 years of work at CERN and ADAM.

The company’s focus is on developing and supplying technologies to maximise the destructive effect of radiation on tumours whilst minimising damage to the patient’s healthy tissues.

11 Aug 2021

Advanced Oncotherapy PLC (LSE:AVO) has proposed a GBP37.4mln equity fundraise as it moves towards completing its first LIGHT proton therapy system, with a 230MeV beam expected by the end of 2021.

The funds are being raised from new and existing investors in a placing and subscription priced at 40p per share, a premium of 17% to the average closing middle market price over the past 30 days.

Advanced Oncotherapy said it intends to use the net proceeds of the share issue to continue the assembly, documentation, verification and validation activities for the first LIGHT system, as well as purchasing the remaining components of the system including payments due to existing supplier Cosylab DD for its services.

In conjunction with the fundraise, the company has entered into a new development and supply agreement with Cosylab.

Read more

30 Jun 2021

() said 2021 is set to be an important year as it aims to have the first LIGHT system generating a full energy beam, alongside the start of treating patients with clinical partner UHB.

The firm said it has made progress at its Daresbury site over the past year, while the ongoing work at the site to optimise its machine installation process will reduce the start-up time for future LIGHT systems and support the assembly of future machines through commercial contracts.

Read more

03 Jun 2021

() said it signed a letter of intent with Saba Partners for the proposed purchase of a three-treatment room LIGHT system for a total contract value of up to US$107mln (GBP75.5mln).

The AIM-listed firm is a developer of next-generation proton therapy systems for cancer treatment, called LIGHT systems, while Saba is an investment advisory and asset management firm based in Geneva with decades of experience in healthcare services and healthcare real estate.

Read more

09 Aug 2019

Proton therapy, a very precise kind of radiotherapy to treat cancer, has only recently become available to patients in the UK and it is still reserved to a narrow group of patients.

Before joining (), Serandour worked for 15 years as an advisor to some of the largest as well as some of the most innovative healthcare firms and saw first-hand how technologies have changed the healthcare landscape.

Read more

03 Jun 2021

‘s () agreement with Saba Partners, an investment consultant in the Gulf region, potentially opens the door to additional markets, says research house goetzpartners.

The letter of intent announced today relates to a single system to be installed in Glion, Switzerland with a contract value of up to US$107mln (GBP75.5mln).

Goetzpartners, which has a target price of 135p and ‘outperform’ rating, adds it had already factored in deals such as this into its forecasts but with the first operational system now close to completion, commercial traction is now the key driver.

Read more

22 Mar 2021

‘s () Jonathan Farr, Chief Clinical Officer, talks to Proactive London’s Katie Pilbeam about their latest findings in regard to resistant cancers.

The firm recently announced to their investors that it had demonstrated superiority of its LIGHT technology in ‘biologically enhanced particle therapy’ to treat these resistant cancers.

Farr explains, these cancers are responsible for most relapses and one of the major causes of death in cancer.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is…

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash…


Market Report: Rising oil prices remind investors of the inflation risk brewing

FTSE100 beat a retreat in early trading as rising oil prices reminded investors of the inflation risk brewing. London’s blue-chip index dropped 45 to 7,062.

Adding to the concerns, petrol prices are at a two-year high according to the RAC. A litre now costs129.27p on average, the highest…

on 3/6/21

2 min read


Please enter your comment!
Please enter your name here